Mgr. Kateřina Machová (Poláková), Ph.D.

Publikovaná abstrakta

• HIGH SENSITIVITY MUTATION SCREENING AND CLONAL ANALYSIS ALLOWED BY ULTRA-DEEP AMPLICON SEQUENCING UNCOVER THE COMPLEXITY OF BCR-ABL MUTATION STATUS IN PATIENTS TREATED WITH TYROSINE KINASE INHIBITORS
• Algorithms and Processing Pipeline For Error Correction and Detection Of Significant Mutations In The Kinase Domain Of BCR-ABL Analyzed By Next-Generation Sequencing: Implications For Clinical Practice Of Chronic Myeloid Leukemia
• BCR-ABL MUTATED CLONE PROGRESSION AND ELIMINATION IN CML PATIENTS TREATED WITH ABL KINASE INHIBITORS
• BCR-ABL Mutations in Chronic Myeloid Leukemia (CML) Patients (pts) with Failure and Warning to First- and Second-Line Tyrosine Kinase Inhibitor (TKI) Therapy: What Is the Advantage of Next-Generation Sequencing (NGS) over Conventional Sequencing?
• Clinical Relevance of Low Burden BCR-ABL1 Mutations Detectable By Amplicon Deep Sequencing (DS) in Philadelphia-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Patients (pts): The Type of Mutation Matters
• DASATINIB EFFICACY AND TOLERANCE IN THE TREATMENT OF CHRONIC MYELOID LEUKEMIA (CML) PATIENTS RESISTANT/INTOLERANT TO IMATINIB IN THE CONTEXT OF REAL CLINICAL PRACTICE MANAGEMENT
• DASATINIB EVEN AT LOWER DOSES IS AN EFFECTIVE FOR CHRONIC MYELOID LEUKAEMIA TREATMENT IN PATIENTS RESISTANT OR INTOLERANT TO IMATINIB
• DEEP SEQUENCING OF THE BCR-ABL KINASE DOMAIN REVEALS A FREQUENCY OF 35INS INSERTION/TRUNCATION HIGHER THAN EXPECTED
• DEFINING LOW AND UNDETECTABLE LEVELS OF DISEASE IN CHRONIC MYELOID LEUKAEMIA: PROGRESS TOWARDS STANDARDISATION IN EUROPE
• DEFINITIONS AND STANDARDISATION OF ‘COMPLETE’ MOLECULAR RESPONSE IN CHRONIC MYELOID LEUKEMIA
• Detection of BCR-ABL Mutation by High Resolution Melting Analysis Is Affected by the Sequence Content, Position and Type of Nucleotide Change and DNA Dye Together with Salt Composition of PCR Mixes
• Differential Expression of miRNAs during the Course of Chronic Myeloid Leukemia
• Dissecting the Complexity of Philadelphia-Positive Mutated Populations by Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain: Biological and Clinical Implications
• DNA Based Detection and Quantification of BCR-ABL1 Gene Using Patient-Specific qPCR and Droplet Digital PCR Tests in Chronic Myeloid Leukemia
• DYNAMICS OF EXPANSION OF TYROSINE KINASE INHIBITOR-RESISTANT MUTANTS AS ASSESSED BY DEEP SEQUENCING OF THE BCR-ABL KINASE DOMAIN: IMPLICATIONS FOR ROUTINE MUTATION TESTING
• EFFICACY AND SAFETY OF IMATINIB IN THE FIRST LINE CHRONIC MYELOID LEUKEMIA (CML) TREATMENT. AN ANALYSIS OF A COMPREHENSIVE POPULATION-BASED DATABASE
• ESTIMATION OF THE CURRENT SURVIVAL MEASURES IN CHRONIC MYELOID LEUKEMIA: METHODOLOGY AND NEW SOFTWARE TOOLS
• EXPRESSION LEVELS OF MIR-150 AND TRANSCRIPTION FACTORS PU.1, EGR2 INVERSELY CORRELATE WITH MYB AND MYCN IN CHRONIC MYELOID LEUKEMIA
• Expression of Four Major WT1 Splicing Variants in AML and CML: Development of Quantitative Real-Time PCRs and Preliminary Results in Patient Samples
• EXPRESSION PATTERN OF WT1 ISOFORMS IN PATIENTS WITH CHILDHOOD AML
• FIRST INTERIM ANALYSIS OF A PAN-EUROPEAN STOP TRIAL USING STANDARDIZED MOLECULAR CRITERIA: RESULTS OF THE EURO-SKI TRIAL
• GENOMIC BCR-ABL1 FUSION CHARACTERISATION AND SNPS IDENTIFICATION UPSTREAM AND DOWNSTREAM OF THE BREAKPOINTS IN BCR AND ABL1 GENES OF CML PATIENTS USING NEXT GENERATION SEQUENCING
• Harmonized Testing for BCR-ABL Kinase Domain Mutations In CML: Results of a Survey and First Control Round within 28 National Reference Laboratories In Europe
• Harmonized Testing for BCR-ABL1 Kinase Domain Mutations In CML: Final Results of a Survey and First Control Round within 24 National Reference Laboratories In Europe
• HAS SIMULTANEOUS PREGNANCY NEGATIVELY INFLUENCED PROGRESSION AND TREATMENT RESPONSE IN CML?
• IMATINIB IN THE FIRST LINE CHRONIC MYELOID LEUKEMIA (CML) TREATMENT. CAN WE COMPARE THE REAL-LIFE DATA TO CLINICAL TRIAL RESULTS?
• IMATINIB IN THE FIRST-LINE CML TREATMENT: AN ANALYSIS OF A COMPREHENSIVE NON-COMMERCIAL DATABASE OF ALL CONSECUTIVE PATIENTS IN A DEFINED POPULATION
• In Chronic Myeloid Leukemia Patients on 2nd-Line Tyrosine Kinase Inhibitor Therapy, Deep Sequencing at the Time of Warning May Allow Sensitive Detection of Emerging BCR-ABL1 Mutants
• INTERFERON-ΑLPHA REVISITED: INDIVIDUALIZED IMMUNE-MODULATION EASED UP SELECTION PRESSURE OF TKI ON BCR-ABL MUTATED CLONES AND IMPROVES MOLECULAR RESPONSE IN HIGH-RISK CML PATIENTS
• Interim Analysis of a Pan European Stop Tyrosine Kinase Inhibitor Trial in Chronic Myeloid Leukemia : The EURO-SKI study
• INTERNATIONAL CONTROL ROUND FOR DEEP SEQUENCING ANALYSIS OF BCR-ABL KINASE DOMAIN MUTATIONS IN 11 LABORATORIES FROM 7 EUROPEAN COUNTRIES
• IS THE HIGH-THROUGHPUT DROPLET DIGITAL PCR A NEXT-GENERATION TECHNOLOGY FOR ACCURATE AND SENSITIVE BCR-ABL1 QUANTIFICATION FOR DEEP MOLECULAR RESPONSE MONITORING IN CML?
• Kdy a jak analyzovat mutace v kinázové doméně BCR-ABL u pacientů s CML?
• Minimal Residual Resistance In CML: Stable BCR-ABL Gene Expression at Levels 0.01–0.1% (IS) In the Consecutive Samples May Be Associated with BCR-ABL Mutation Development and MMoR Lost In a Small Number of Tyrosine Kinase Inhibitor Responders
• Minor Subclones Harboring Small Insertions and Deletions Probably Due To Aberrant Splicing Can Frequently Be Detected By Deep Sequencing of The BCR-ABL Kinase Domain
• MIR-451 MAY POSITIVELY REGULATE MDR1 IN CHRONIC MYELOID LEUKEMIA
• Modeling Resistance To Tyrosine Kinase Inhibitors In TEL/ABL-Positive Acute Lymphoblastic Leukemia
• MODELING RESISTANCE TO TYROSINE KINASE INHIBITORS IN TEL/ABL+ ACUTE LYMPHOBLASTIC LEUKEMIA
• MRD Monitoring Using Minor-BCR-ABL1 Genomic Breakpoint in Childhood ALL Identifies a Subgroup with Distinct Biology and a Very Poor Prognosis
• Patients with Chronic Myeloid Leukemia Show Different Modulation of MYB-Dependent Oncogenic Pathway in the Course of Hematopoietic Differentiation upon Sensitivity to the TKI Treatment
• PREDICTION OF IMATINIB THERAPY RESPONSE: A ROLE OF INTRACELLULAR TRANSPORTERS HOCT-1 AND ABCB1
• Role of the MSC-Derived Exosomal and Endogenous JAK2-SET/PP2A-Beta Catenin-Modulator Mir-300 in Leukemic Stem/Progenitor Proliferation and Survival in CML
• Sensitivity, Reproducibility and Clinical Utility Of Next-Generation Sequencing (NGS) for BCR-ABL1 Kinase Domain Mutation Screening: Results From The CML Work Package Of The Iron-II (Interlaboratory RObustness Of Next-Generation Sequencing) International Study
• SHORT WT1 VARIANT OF WILMS TUMOR GENE IS EXPRESSED IN LEUKEMIC CELL LINES, PATIENTS WITH AML, MDS AND IN CML BLAST CRISIS
• SNPs in the Promoter of the Gene Encoding Transmembrane Transporter SLC22A4 (hOCTN1) Are Significantly Associated with an Alteration of Gene Expression and with Resistance to the Imatinib Treatment in Chronic Myeloid Leukemia
• SUCCESSFUL MANAGEMENT OF CML DURING PREGNANCY AND IN POST-PARTUM PERIOD
• The Gene Expressions of hOCT1 and ABCB1 Change During the Course of CML in Relation to Imatinib Therapy
• THE IMPACT OF THERAPY INTENSIFICATION AND OUTCOME OF 6 CML PATIENTS WITH THE SAME TYPE OF BCR-ABL MUTATION M244V
• The Interlaboratory Robustness of Next-Generation Sequencing (IRON) Study Phase II: Deep-Sequencing Analyses of Hematological Malignancies Performed by an International Network Involving 26 Laboratories
• The Interlaboratory Robustness Of Next-Generation Sequencing (IRON) Study Phase II: Deep-Sequencing Analyses Of Hematological Malignancies Performed In 8,867 Cases By An International Network Involving 27 Laboratories
• The Outcome of Unselected Patients with Chronic Myeloid Leukemia (CML) In Chronic Phase (CP) Treated with Imatinib In the First Line and the Prognostic Value of ELN Defined Responses – Population Based Analysis of 458 Patients Treated Between 2003–20
• The Plateau of BCR-ABL Transcript Level =;>0.1% May Select CML Patients in Complete Cytogenetic Remission for Mutation Analysis.
• Ultra Deep Sequencing (UDS) Allows More Sensitive Detection Of Tyrosine Kinase Inhibitor (TKI)-Resistant BCR-ABL Mutations That Would Influence Therapeutic Decision At The Time Of Switchover To Second- Or Third-Line Therapy
• Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain Allows Earlier Detection and More Accurate Characterization of Resistant Subclones in Philadelphia-Positive Acute Lymphoblastic Leukemia Patients Receiving Tyrosine Kinase Inhibitor-Based Therapies
• ULTRA-DEEP SEQUENCING WITH COMPUTED THRESHOLDS FOR SENSITIVE MUTATION ANALYSIS IN THE KINASE DOMAIN OF BCR-ABL: FOCUSED ON DEEP MUTATION DETECTION IN CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE
• Ultradeep-Amplicon Pyrosequencing for Mutation Detection in the Kinase Domain of BCR-ABL Revealed Artificial Low-Level Variants That Need to Be Avoided for Relevant Mutational Data Interpretation